That is according to a new study, which suggests that weight-loss jabs, officially GLP-1 receptor agonists, could almost halve the risk of obesity-related cancers.

Dr Yael Wolff Sagy, the study's co-lead author, said: "We do not yet fully understand how GLP-1s work, but this study adds to the growing evidence showing that weight loss alone cannot completely account for the metabolic, anti-cancer, and many other benefits that these medications provide."

The NHS claims that obesity is the second biggest cause of cancer in the UK. Obesity actually causes more than one in 20 cancer cases, according to the NHS.

But the recent research found that weight-loss injections are 41 percent more effective at "preventing obesity-related cancer".

Professor Dror Dicker, who co-authored the study, added: "New generation, highly potent GLP1-RAs with higher efficacy in weight reduction may convey an even greater advantage in reducing the risk of obesity-related cancers."

Despite this, Naveed Sattar - who is a professor of cardiometabolic medicine at the University of Glasgow - warned that the study "cannot confirm or refute any links of incretin-based therapies [medicines to treat type 2 diabetes] with cancer as the design was not a trial but rather observational".